Drugs / Bezlutifan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02293980 Background | Nov 2014 → Jan 2017 overdue | clear cell renal carcinoma | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bezlutifan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02293980 ↗ |
| Route | Oral | “belzutifan 120 mg once daily (QD)” NCT02293980 ↗ |